NAS:IONS (USA)
Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Compare
Compare
Traded in other countries / regions
ISI.Germany
•
IONS.Mexico
•
IONS.Switzerland
•
0JDI.UK
•
IONS.USA
Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.68 | |||||
| Equity-to-Asset | 0.28 | |||||
| Debt-to-Equity | 1.72 | |||||
| Debt-to-EBITDA | 64.98 | |||||
| Interest Coverage | 5.83 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.7 | |||||
| Beneish M-Score | -2.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.7 | |||||
| 3-Year EBITDA Growth Rate | 36 | |||||
| 3-Year FCF Growth Rate | -72.5 | |||||
| 3-Year Book Growth Rate | -10.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -11.01 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.24 | |||||
| 9-Day RSI | 69.73 | |||||
| 14-Day RSI | 67.52 | |||||
| 6-1 Month Momentum % | 9.2 | |||||
| 12-1 Month Momentum % | -3.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.86 | |||||
| Quick Ratio | 9.76 | |||||
| Cash Ratio | 8.98 | |||||
| Days Inventory | 693.22 | |||||
| Days Payable | 355.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.52 | |||||
| Operating Margin % | 1.86 | |||||
| Net Margin % | -0.46 | |||||
| ROE % | -0.59 | |||||
| ROA % | -0.16 | |||||
| ROIC % | 4.05 | |||||
| ROC (Joel Greenblatt) % | -0.44 | |||||
| ROCE % | -0.04 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.73 | |||||
| PB Ratio | 9.21 | |||||
| Price-to-Tangible-Book | 9.61 | |||||
| Price-to-Free-Cash-Flow | 183.68 | |||||
| Price-to-Operating-Cash-Flow | 121.32 | |||||
| EV-to-EBIT | -7224.14 | |||||
| EV-to-Forward-EBIT | -14.37 | |||||
| EV-to-EBITDA | 303.42 | |||||
| EV-to-Forward-EBITDA | -15.09 | |||||
| EV-to-Revenue | 6.78 | |||||
| EV-to-Forward-Revenue | 9.25 | |||||
| EV-to-FCF | 153.93 | |||||
| Price-to-Projected-FCF | 2.74 | |||||
| Price-to-Median-PS-Value | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 14.73 | |||||
| Price-to-Net-Cash | 26.96 | |||||
| Earnings Yield (Greenblatt) % | -0.01 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:IONS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 840.768 | ||
| EPS (TTM) ($) | -0.2 | ||
| Beta | 0.6 | ||
| Volatility % | 32.86 | ||
| 14-Day RSI | 67.52 | ||
| 14-Day ATR ($) | 1.86403 | ||
| 20-Day SMA ($) | 39.7205 | ||
| 12-1 Month Momentum % | -3.66 | ||
| 52-Week Range ($) | 25.04 - 46.15 | ||
| Shares Outstanding (Mil) | 141.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||